Sergio Emanuel Kaiser: Ruvonoflast and a New Anti-Inflammatory Strategy for Residual Cardiovascular Risk
Sergio Emanuel Kaiser, Coordinator at UERJ – Discipline of Clinical and Experimental Pathophysiology, Associate Professor of Medicine at Rio de Janeiro State University, shared a post on LinkedIn about a recent article by Kausik Ray, published in JACC, adding:
“EAS Congress 2026.
A new actionable pathway is tested in a phase 1 study by Kausik Ray and collaborators.
Rivonoplast, a potent inhibitor of NLRP3 inflamassome led to early and sustained reversible sCRP reduction compared to placebo.
Some pictures from his presentation depicted below.”
Title: Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk
Authors: Kausik K. Ray, Nicholas Clarke, Peter Thornton, Amy E. Miles, Zsofia Digby, Melanie J. Davies, Michelle Gorman, Bianca Mullen, Valérie Reader, Missy Magill, Hilary Johnstone, Cono Ariti, Naveed Sattar, Nikolaus Marx, Ann Marie Navar, Adrian F. Hernandez, Jyothis T. George, Alan P. Watt, Javed Butler, Paul M. Ridker

Stay updated on all scientific advances with Hemostasis Today.
-
May 29, 2026, 09:50Maria Symiakaki: Advancing Cardiovascular Prevention at the 2026 Congress of the European Atherosclerosis Society
-
May 29, 2026, 09:37Katie Baca-Motes: What Can Menstrual Cycle Physiology Tell Us About Health Beyond Reproduction?
-
May 29, 2026, 09:35Torben Boelk: Bringing Plasma Donation to the Heart of Leipzig
-
May 29, 2026, 04:37Josefin Ahnström: How Andexanet Alfa Impacts TFPIα Function
-
May 29, 2026, 03:19Building Safer Systems for Anticoagulation Management – ISTH
-
May 29, 2026, 03:07Early Diagnosis Can Change the Lives of Women With Haemophilia – EHC
-
May 29, 2026, 02:41Ifeanyichukwu Ifechidere: The Biggest DOAC Myth in Coagulation – ‘No Monitoring Required’
-
May 29, 2026, 02:35Mariam Swidan: Why Is LDH the ‘Tattletale’ of the Lab?
-
May 29, 2026, 02:20Yuntian Wang: Multi-View Learning for Predicting Avatrombopag Response in Pediatric Immune Thrombocytopenia